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Background. Atherosclerotic artery disease is a common con-
dition in patients with chronic kidney disease (CKD); however,
there are few published data on the prevalence of peripheral ar-
terial disease (PAD) in nondialyzed patients with renal insuffi-
ciency. The ankle-brachial index (ABI) is a simple, noninvasive,
and reliable method to assess PAD.
Methods and Results. Prevalence of PAD using ABI was
investigated in 102 patients referred for the first time to a
nephrology clinic with CKD in stages 3 to 5 of the K/DOQI
classification, and with no previous diagnosis of PAD. Patients
with ABI <0.9 were considered positive for PAD.
A total of 64% of the patients were male. The mean age
was 70 ± 11 (range 58–84) years, and the estimated creatinine
clearance (CrCl) was 35 ± 12 (range 6–59) mL/min−1. Of the
total sample, 26% were diabetics, 10% active smokers, 48%
ex-smokers, and 29% had a diagnosis of coronary heart dis-
ease (CHD), 15% had been previously diagnosed of stroke,
and 17% had signs and symptoms compatible with intermittent
claudication, which had passed unnoticed. Thirty-two percent
of patients had an ABI <0.9 (mean 0.64 ± 0.25). Of these pa-
tients with PAD, 84% were men (P < 0.005), and only 30%
presented a clinical picture compatible with intermittent clau-
dication. Absolute risk of CHD according to the Framingham
1998 score was higher in the PAD group (19.3% ± 6 vs. 13.1% ±
8; P = 0.01). Patients with PAD were older (75 ± 6 vs. 66 ± 11
years, P = 0.000), and had worse renal function (CrCl 30.8 ±
12 vs. 37 ± 10.7 mL.min−1, P = 0.016) compared to patients
without PAD, but no differences were found in cholesterol lev-
els (total, HDL, LDL), calcium, phosphorus, or PTH. In the
logistic regression analysis, independent indicators of PAD risk
were male sex, age, and lower CrCl.
Twelve percent of patients had an ABI ≥1.3, suggestive of
parietal arterial calcifications. In these patients, systolic blood
pressure and pulse pressure were lower (126 ± 18 vs. 150 ± 27,
P = 0.005, and 52 ± 13 vs. 68 ± 25 mm Hg, P = 0.044), i-PTH
levels were higher (228 ± 267 vs. 117 ± 63 pg/mL, P = 0.01),
and a larger proportion of this group was treated with calcitriol
(34% vs. 13%) compared to patients with a normal ABI.
Conclusion. A high prevalence of PAD, considered as an ABI
<0.9, was demonstrated in nondialyzed patients with CKD. This
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was related with age, male sex, and higher degree of renal in-
sufficiency, while the presence of ABI ≥1.3 was associated with
a greater degree of hyperparathyroidism. These data show the
need to carry out routine ABI determinations in patients with
CKD for early detection of peripheral arterial disease.
Patients with chronic kidney disease (CKD) are highly
predisposed for developing accelerated atherosclerosis,
even in the absence of certain traditional cardiovascular
risk factors [1]. Moreover, frequently these patients not
only present traditional risk factors such as hypertension,
diabetes, or dyslipidemia, but also other nontraditional
factors such as inflammation, malnutrition, and oxida-
tive stress, which enhance and accelerate atherosclerosis.
Minor renal dysfunction influences cardiovascular risk
[2–5]. Although the relationship between myocardial in-
farction, stroke, and cardiovascular death with renal dys-
function is well established, there are few data on the
prevalence of peripheral arterial disease (PAD) in the
lower extremities in patients with CKD. PAD is associ-
ated with high mortality, 3 times higher than that of the
general population [6], even in patients without CKD,
and its prevalence appears to be much higher among
end-stage renal disease patients, as evidenced by the high
amputation rates in this group compared to the general
population [7]. However, it has not been as extensively
studied as other atherosclerotic diseases, such as coronary
artery disease and cerebrovascular disease, and there are
few data about its prevalence in earlier stages of CKD. A
recently published study based on data from the National
Health and Nutrition Examination Survey (NHANES)
1999 to 2000 on PAD in individuals with renal insuffi-
ciency using the ankle-brachial index (ABI) confirmed
the high prevalence of PAD, defined by an ABI <0.9,
among patients with renal insufficiency in nonadvanced
stages (CrCl<60 mL/min−1/1.73m−2), independent of pa-
tient’s age, diabetes, coronary disease, stroke history, and
hypercholesterolemia. This implies that routine use of
ABI measurements in these patients would greatly in-
crease detection of subclinical PAD [8].
S-44
de Vinuesa et al: Prevalence and related risk factors S-45
ABI is a noninvasive diagnostic test that is easy to per-
form, reproducible, and efficient in detecting subclinical
PAD. It has also been shown to be a strong predictor
of cardiovascular disease and of mortality. An ABI <0.9
is 95% sensitive and 100% specific for angiographically
documented PAD for arterial stenosis ≥50% in the lower
extremities [9, 10].
In the present work, we investigated the prevalence
and risk factors associated with subclinical PAD in non-
dialyzed patients with CKD with varying degrees of renal
insufficiency using the ABI.
METHODS
This study was done between October 2003 and April
2004 in adult patients referred for the first time to the
nephrology outpatient clinic. We included 102 patients
of both sexes with stages 3 to 5 of CKD (K/DOQI) not
previously diagnosed with PAD, defined as an atheroscle-
rotic disease that causes ischemia in the legs, con-
firmed by arteriography, vascular Doppler, or treated
with surgery, stent, or amputations. All patients had CrCl
<60 mL/min−1 calculated using the Cockroft-Gault for-
mula [11] and were hypertensive receiving drug therapy,
47% had dyslipidemia treated with statins, and 45% re-
ceived antiplatelet treatment. Patients on dialysis, renal
transplants, or with an arteriovenous fistula were all ex-
cluded. The renal disease had a vascular etiology in 24%,
diabetic nephropathy in 16%, unknown in 26%, chronic
interstitial nephropathy in 13%, and was associated with
other causes in the remaining 21%.
Twenty-six percent of patients had type 2 diabetes,
29% had coronary heart disease confirmed by coronari-
ography, a previous myocardial infarction, or surgery or
coronary revascularization, and another 15% had cere-
brovascular disease with a clinical history of stroke with
neurologic deficit, or confirmed by arteriography, com-
puterized tomography, magnetic resonance, or surgical
treatment/stent of the carotid arteries.
Patients were considered to be active smokers if they
had smoked at all during the last month; ex-smokers if
they had ever smoked; and nonsmokers if they had never
smoked.
For all patients, the ABI was calculated using a portable
pulse detector (Ultrasonic Mini Doppler ES-100;
Hadeco, Inc., Arima, Japan) and an 8 mHz probe. Sys-
tolic blood pressure (SBP) measurements were taken in
both arms and legs after 5 minutes at rest in decubitus
supine. The ABI was calculated for each leg on the basis
of the SBP of the arm where this was highest and accord-
ing to the formula:
SBP in posterior tibial artery or dorsalis pedis
artery/brachial SBP
Table 1. Patient characteristics
No. of patients 102
Sex % males 64%
Age years 70 ± 11
SBP mm Hg 148 ± 23
DBP mm Hg 79 ± 12
PP mm Hg 68 ± 19
Diabetes % 26
Smokers % 10
Dyslipidemia % treated with statins 47
Coronary heart disease % 29
Cerebrovascular disease % 15
Antiplatelet therapy % 45
Calcitriol treatment % 14%
BMI kg/m−2 29 ± 11
An ABI ≥0.9 and <1.3 in both legs was considered as
normal, and patients were diagnosed as having PAD if
the value recorded for one of the legs was <0.9 or ≥1.3.
In all patients, absolute risk of coronary heart dis-
ease within the next 10 years was calculated based on
Framingham’s score for men and women [12].
Table 1 shows the characteristics of the patients in-
cluded in the study.
Statistic methodology
Data are expressed as mean ± SD. All statistic analysis
was performed using a computerized statistical package
(SPSS for Windows, version 11.01; SPSS, Inc., Chicago,
IL, USA). Chi-square test was used for qualitative vari-
ables, and Student t test was used to analyze differences
in the continuous variables between pathologic and nor-
mal ABI. Finally, multiple logistic regression analysis was
done.
RESULTS
Fifty-seven patients (56%) had a normal ABI, 33
(32%) had an ABI <0.9, and 12 (12%) an ABI ≥1.3.
The differences between patients with a normal and a
pathologic ABI are shown in Table 2.
Patients with an ABI <0.9 were mainly older, male,
ex-smokers with a worse renal function, and lower DBP
measurements. Calculation of the absolute risk of coro-
nary disease in the following 10 years revealed a high risk
of near 20%. Of these patients with an ABI <0.9, only
30% had signs and symptoms compatible with intermit-
tent claudication, defined as pain on walking that disap-
peared when resting, and all others were asymptomatic.
None referred to pain while resting. Multiple logistic re-
gression analysis demonstrated that the risk factors for
an ABI <0.9 were older age, male sex, and a lower CrCl
(Table 3).
Twelve percent of patients had an ABI ≥1.3. These pa-
tients were usually diabetics, had higher LDL-cholesterol
levels, and lower blood pressure levels, but there were
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Table 2. Comparison of patients with a normal ABI (between 0.9 and 1.3) and a pathologic one
ABI ABI ABI
≥0.9 to 1.3 <0.9 ≥1.3
(N:57) (N:33) (N:12) Pa Pb
ABI 1.08 ± 0.1 0.64 ± 0.25 1.4 ± 0.2 .000 .000
Male gender % 54 84 58 <0.005 NS
Age years 66 ± 11 75 ± 6 71 ± 9 .000 NS
Smoking history %c 53 29 35 <.02 NS
Diabetes mellitus % 26 26 33 NS <.05
CHD % 26 32 33 NS NS
CVD % 13 16 25 NS NS
SBP mm Hg 150 ± 27 148 ± 22 126 ± 18 NS .005
DBP mm Hg 82 ± 13 75 ± 14 74 ± 6 .023 .032
PP mm Hg 68 ± 25 72 ± 17 52 ± 13 NS .044
BMI kg/m−2 29 ± 12 26 ± 3 30.1 ± 14 NS NS
Plasma Cr mg/dL−1 1.9 ± 0.8 2.46 ± 1.8 1.8 ± 0.5 NS NS
ClCr mL/min−1 37 ± 10.7 30.8 ± 12 41 ± 38 .016 NS
Total chol mg/dL−1 197 ± 40 191 ± 40 220 ± 43 NS NS
HDL-chol mg/dL−1 59 ± 21 55 ± 18 55 ± 14 NS NS
LDL-chol mg/dL−1 113 ± 32 115 ± 35 136 ± 33 NS .043
Calcium mg/dL−1 9.4 ± 0.6 9.2 ± 0.4 9.4 ± 0.6 NS NS
Phosphate mg/dL−1 3.4 ± 0.6 3.5 ± 1.2 2.9 ± 0.33 NS .038
i-PTH pg/mL−1 117 ± 63 101 ± 70 228 ± 267 NS .01
AR % 13.1 ± 8.1 19.3 ± 6.1 15.1 ± 8.3 .012 NS
Calcitriol treated patients % 13 10 34 NS <0.05
Abbreviations are: CHD, coronary heart disease; CVD, cerebrovascular disease; AR, absolute risk (Framingham 1998). Mean ± SD.
aUnpaired t test or v 2 test: ABI ≥ 0.9 to 1.3 vs. ABI < 0.9.
bUnpaired t test or v 2 test: ABI ≥ 0.9 to 1.3 vs. ABI ≥ 1.3.
c% of patients who have never smoked.
Table 3. Multiple logistic regression analysis
B S.E. Exp (B) 95% CI P value
Sex −1.497 .5854 .2237 .0360–.6639 .0105
Age .0735 .0305 1.0767 1.0122–1.17123 .0160
CCr −0444 .0227 .9566 .9094–1.0009 .0496
no differences in relation to sex, age, or renal func-
tion, although they did have higher i-PTH levels and
lower phosphate levels. They were also more likely
to receive treatment with calcitriol to treat secondary
hyperparathyroidism.
DISCUSSION
Our data confirm a high prevalence of PAD (32%) in
nondialyzed patients with CKD and CrCl <60 mL/min−1,
which contrasts with data published for a Spanish popu-
lation of 130 essential hypertensive patients without re-
nal insufficiency, in which only 6.9% of the sample had
a pathologic ABI [13]. Our prevalence of 32% exceeds
that described by O’Hare et al based on the results of
the National Health and Nutrition Examination Survey
(NHANES) 1999–2000 [8], which investigated 211 pa-
tients with a CrCl <60 mL/min−1, and 50 (24%) were
found to have an ABI <0.9. The difference in prevalence
between both series could be associated with a greater co-
existence of classic risk factors of atherosclerosis between
our patients such as male sex, diabetes, or hypertension.
Of the patients included in our study, 64% were men, 26%
type 2 diabetics, and all were treated hypertensives, com-
pared to the NHANES study in which 52% were men,
only 13% were diabetics, and 57% were hypertensive.
Other classic risk factors, such as smoking or high choles-
terol levels, are not more prevalent in patients with CKD,
and appear in a similar proportion in both series. Leski-
nen et al also studied the prevalence of PAD using ABI
in a Finnish population of 136 patients with chronic renal
failure, which included 59 nondialyzed nontransplanted
patients with plasma creatinine >2.3 mg/dL and CrCl
30 ± 25 mL/min−1. The prevalence of ABI <0.9 was 22%,
compared to 30.6% in dialyzed patients and only 1.7% in
the control group. However, patients over 70 years old
were excluded in this study, and the mean age (54 ± 11
years) was clearly lower than that in our series [14]. It is
interesting to note the high prevalence of ABI >1.3 in the
Finnish study, which was 23.7%, compared to 3.7% in the
NHANES results and 12% in our study. An ABI >1.3
suggests the existence of medial arterial calcification [15]
in patients with CKD, and also a poor prognosis for all-
cause and cardiovascular mortality in patients with CKD
in treatment with hemodialysis [16]. In both our data and
the Ono study, those patients with ABI >1.3 had lower
blood pressure and pulse pressure levels than patients
with a normal ABI or ABI <0.9, for no clear reason.
In spite of an irrefutable association between CKD and
PAD, we cannot guarantee that the renal insufficiency is
merely an indicator of generalized atherosclerosis [17],
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although there seems to be a causal relationship between
renal insufficiency and atherosclerosis progression in the
legs, with possible involvement of pathogenic mecha-
nisms associated with reduced glomerular filtration, such
as alterations in the metabolism of calcium, phosphate,
and parathyroid hormone, hyperhomocysteinemia, in-
flammatory alterations, or alterations in the coagulation
pathway [7, 18]. Similarly, there was clearly a greater
degree of hyperparathyroidism in our patients with an
ABI >1.3, suggestive of medial arterial calcification, com-
pared to patients with a normal ABI.
Only a third of the patients with pathologic ABI had
intermittent claudication. Given that ABI is a predic-
tor of cardiovascular mortality and morbidity [16, 19],
and a simple noninvasive way to diagnose subclinical
atherosclerotic disease, this should be routinely deter-
mined in patients who can benefit earlier from ther-
apeutic measures aimed at delaying arterial occlusion
progression and distal ischemia. These patients should be
specifically advised about the need for physical exercise,
especially walking, and to give up smoking, where rele-
vant [20]. Antiplatelet drugs are the cornerstones for the
treatment of PAD, but only 48% of our patients with PAD
received antiplatelet treatment for other concurrent med-
ical conditions. The Antiplatelet Triallist’s Collaboration
Study has reported a 25% reduction in cardiovascular
events in PAD patients treated with antiplatelet drugs
compared with those treated with placebo [21], with a
preference for clopidogrel over aspirin in these patients,
although the efficacy of the combined treatment with
both these drugs in this condition has yet to be estab-
lished [22].
CONCLUSION
Our data confirm the high prevalence of PAD in pa-
tients with CKD. The presence of subclinical PAD, eval-
uated by ABI, is correlated with a worse renal function,
and with other classic risk factors such as age and male
sex, and is asymptomatic in a high percentage of cases.
ABI determinations should, therefore, be included in the
routine tests carried out in these patients, in order to in-
stitute, early on, therapeutic measures of confirmed effi-
cacy such as physical exercise and antiplatelet treatment
to prevent progression of vascular disease.
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